United Kingdom Aptamers Market Size, Share, and COVID-19 Impact Analysis, By Type (Nucleic Acid Aptamer and Peptide Aptamer), By Application (Diagnostics, Therapeutics, Research & Development, and Others), and UK Aptamers Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Aptamers Market Forecasts to 2035

• The United Kingdom Aptamers Market Size Was Estimated at USD 112.2 Million in 2024
• The UK Aptamers Market Size is Expected to Grow at a CAGR of around 25.65% from 2025 to 2035
• The UK Aptamers Market Size is Expected to Reach USD 1382.8 Million by 2035

According to a research report published by Spherical Insights & Consulting, The UK Aptamers Market Size is anticipated to reach USD 1382.8 Million by 2035, growing at a CAGR of 25.65% from 2025 to 2035. The increased demand for targeted therapies, improved SELEX technology, emphasis on personalized medicine, and strong government and private funding, the UK aptamers market is experiencing growth. Their potential for diagnostics and therapeutics, combined with diversity in applications, is enabling further uptake of aptamers in the healthcare and research industries.

Market Overview

The UK aptamers market refers to short single-stranded DNA or RNA molecules that are used as substitutes for antibodies because of their remarkable selectivity in binding particular targets. They are used in the treatment of cancer, viral infections, and in the diagnostics and detection of other diseases. Aptamers are useful for precision medicine, drug delivery, and discovery, while being inexpensive, non-immunogenic, and easily modified. Recent progress in aptamer development, purification, and targeted drug delivery has sparked growing interest among researchers due to their unique advantages. These include small molecular size, low immunogenicity, cost-effective production, and fewer side effects compared to antibodies. Such benefits are expected to accelerate research and development of novel aptamers, boosting market growth. Although no highly effective COVID-19 treatment exists due to frequent mutations, biotechnological methods like aptamer-based diagnostics using SELEX technology show promise. These kits are capable of producing high-affinity neutralizers and bioprobes able to detect biomarkers of SARS-CoV-2. The superior specificity and efficacy of aptamer-based products make them advantageous for disease diagnosis at the cellular level, especially for pathology and diagnostic laboratories and services. The demand for aptamer-based diagnostics and bioprobes will grow substantially during the forecast period due to increasing cases of diseases like cancer, cardiovascular disease, and age-related macular degeneration (AMD) around the UK.

Report Coverage

This research report categorizes the market for the UK aptamers market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom aptamers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom aptamers market.

Driving Factors

The increasing demand for personalized medicine and targeted treatments, especially for cancer and chronic diseases, is contributing to the rapid growth of the aptamers market. Aptamers are ideal for precision therapeutics because of their low side effects and specificity. With advances in synthesis methods and technology, such as SELEX, the development costs have decreased with increased diagnostic and therapeutic applications. Also, increasing public and private funding has encouraged partnership, accelerated research and development, initiated clinical trials, and driven the development of aptamer-based biopharmaceutical products and solutions.

Restraining Factors

The barriers for aptamers are regulatory approval and clinical validation in comparison to the more established treatments based on antibodies. Their predominant factor to penetrate the market is limited acceptance limited by physiological stability, large-scale production, and a lack of standardised protocols for application, subsequently discouraging investment and delaying commercialisation of therapeutic use. These factors hamper the aptamers market during the forecast period.

Market Segmentation

The United Kingdom aptamers market share is classified into type and application.

• The nucleic acid aptamers segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom aptamers market is segmented by type into nucleic acid aptamers and peptide aptamers. Among these, the nucleic acid aptamers segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Many companies are examining how nucleic acid aptamers can be used to treat numerous conditions, specifically age-related muscle degeneration (AMD). DNA and RNA aptamers have many applications in diagnostics and treatment for targeting a large number of biomolecules because of their chemical stability, ability to be mass-produced with ease, and capacity to be developed for various applications.

• The research & development segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom aptamers market is segmented by application into diagnostics, therapeutics, research & development, and others. Among these, the research & development segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The significance of aptamers has been appreciated by the most sophisticated R&D in the UK. Because of their unique qualities and adaptable applications across many different sectors, the roles of aptamers are constantly being investigated by researchers. Aptamers show great potential in the diagnosis and treatment of a variety of diseases. Economic growth is being driven by increased spending in the pharmaceutical R&D and biotechnology sectors.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom aptamers market and a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Aptamer Group
• AMSBIO
• ATDBio Ltd
• Aptalink Therapeutics
• Tissue Click
• Silence Therapeutics PLC
• Others

Key Target Audience

• Investors
• Market players
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom aptamers market based on the below-mentioned segments:

United Kingdom Aptamers Market, By Type

• Nucleic Acid Aptamer
• Peptide Aptamer

United Kingdom Aptamers Market, By Application

• Diagnostics
• Therapeutics
• Research & Development
• Others